Back to list

Semaglutide P29 peptide intermediate: Structure, Fermentation Route, and Quality

Published on November 10, 2026

Semaglutide P29 peptide intermediate: Structure, Fermentation Route, and Quality

figure1. Fermentation production route of the Semaglutide P29 peptide intermediate.



1. What the Semaglutide P29 peptide intermediate Is

The core conclusion first: the Semaglutide P29 peptide intermediate is the 29-amino-acid backbone of semaglutide, and it is the piece whose purity and consistency govern how cleanly the rest of the API can be assembled.

1.1 The 29-Amino-Acid Backbone

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used in type 2 diabetes and weight management. It is assembled in stages, and the stage that defines the drug is the main chain.

• The identity. The Semaglutide P29 peptide intermediate is the 29-amino-acid chain written as Arg34GLP-1(9-37), commonly called the semaglutide 29-peptide backbone. It carries the sequence from residue 9 to residue 37 of the native GLP-1 peptide.

• The sequence. The backbone runs Glutamate-Glycine-Threonine-Phenylalanine-Threonine-Serine-Aspartate-Valine-Serine, continuing through the lysine and the hydrophobic core to the C-terminal Glycine-Arginine-Glycine. The arginine at position 34 and the lysine at position 26 are the landmarks most often checked for identity.

• The CAS number. The material is referenced by the CAS registry number 1169630-82-3.

1.2 Where It Sits in Semaglutide API Assembly

The intermediate is not the final drug. It is the core that comes before the modifications.

• The backbone is the starting scaffold. The N-terminal extension and the fatty-acid side chain are attached to the backbone after it is in hand.

• It carries the structure that binds the receptor. The receptor-binding sequence lives in this 29-mer, so any error here propagates into the API.

• It is the piece you source. For most manufacturing platforms, the intermediate is produced at scale and then modified, which is why it is bought and sold as a distinct material.

1.3 Why the Backbone Sets the Downstream Quality Ceiling

The properties of the intermediate are not cosmetic.

• It determines the purity baseline. The API cannot be cleaner than the chemistry that feeds it, so a high-purity intermediate reduces downstream work.

• It sets the impurity seed. Host-related and fusion-related species carried into the intermediate have to be handled later.

• It controls batch consistency. If the intermediate varies from batch to batch, the modification step and the final product vary too.

1.4 The Commercial Role of the Intermediate

The intermediate is a traded material because it solves a real problem in the supply chain.

• It separates the hard chemistry from the modification. Building a clean 29-mer is a distinct challenge, and once it is solved, the N-terminal extension and the side chain can be handled separately.

• It lets a team own the downstream step. A developer who buys the intermediate can control the modification chemistry and the final assembly without running a peptide synthesis plant.

• It is where quality is decided. Purity, impurity control, and batch consistency are largely set at the intermediate stage, and they propagate into the API.


2. The Fermentation Route, Step by Step

The core conclusion first: the fermentation route for the Semaglutide P29 peptide intermediate is a three-stage pipeline, and most of the quality is decided in the cleavage and chromatography steps rather than in the expression itself.


Release of the Semaglutide P29 peptide intermediate backbone from a fusion precursor by site-specific cleavage.

figure2. Release of the Semaglutide P29 peptide intermediate backbone from a fusion precursor by site-specific cleavage.

2.1 Recombinant Expression: Constructing a High-Expression Strain

The backbone is not isolated from a natural source. It is produced by a recombinant host engineered to express a fusion precursor.

• The goal. Build a high-expression strain that accumulates the precursor in a form that is easy to recover.

• The sequence design. The P29 sequence is fused to a carrier and a linker that carries the cleavage site. The linker design determines how the chain is later released.

• What can go wrong. Poor expression or an unstable fusion lowers the recovery and can load the stream with host proteins.

2.2 Efficient Enzyme Digestion

The precursor is released by a site-specific protease that cuts at the engineered junction.

• The requirement is specificity. The enzyme must cut at the designed site and nowhere else, so that the released chain carries the correct N-terminus.

• The benefit of a highly specific cut. A clean cut means fewer mis-cleaved fragments and a simpler downstream separation.

• The enzyme choice matters. Enterokinase, Kex2, and carboxypeptidase B address different boundaries, and the route is tuned around the one that matches the precursor.

2.3 Medium-Pressure Preparative Chromatography

After cleavage, the product is purified by preparative chromatography run at medium pressure.

• The role. Chromatography isolates the target peptide from the residual host material, the fusion tag, and the mis-cleaved species.

• The advantage of medium pressure. It balances loading capacity with resolution, so the column handles a large load while still separating closely related impurities.

• The output. A purified intermediate that is then carried to a stable final form.

2.4 Lyophilization and the Final Form

The purified intermediate is converted to a dry, stable solid.

• The step. Lyophilization removes water while preserving the peptide's structure and solubility.

• The reason. A dry powder is more stable and easier to store, ship, and weigh than a solution.

• The form you receive. The Semaglutide P29 peptide intermediate is typically supplied as a lyophilized powder, ready to reconstitute for the downstream modification step.

2.5 What to Verify at Each Step

A good route is only as strong as its verification.

• At expression. Confirm the fusion precursor is produced at the expected level and that the strain is stable across batches.

• At cleavage. Monitor the formation of the complete target, the growth of mis-cleaved fragments, and the total recovery together, not just the total protein.

• At chromatography. Confirm the separation removes the host and fusion-related species and that the collection windows are reproducible.

• At the final powder. Confirm the content basis, the residual solvent and water, and the identity before release.

2.6 Strain and Linker Design: The Decisions That Matter

The route can be tuned before the fermenter ever runs.

• The carrier protein. A well-chosen carrier increases expression and makes the precursor easy to recover from the cell.

• The linker. The linker carries the cleavage recognition sequence. Changing it changes which enzyme can release the chain and whether the N-terminus is native.

• The expression format. Whether the precursor is soluble or forms inclusion bodies changes the recovery strategy and the purification load.

• The practical effect. These choices are made once, and they shape every later step, so they deserve attention before scale-up.


3. Chemical Synthesis vs. Fermentation

The core conclusion first: the two routes differ mainly in cost, scale, and the type of impurities they leave behind. Fermentation is the more common choice for the backbone at commercial scale.

3.1 Solid-Phase Chemical Synthesis

In this route, amino acids are coupled onto a resin one at a time.

• Advantage. Fully programmable; any sequence can be built on demand, and labeled analogs are possible.

• Limitation. For a 29-residue chain, coupling efficiency compounds, and the risk of deletion sequences and epimers grows.

• Cost profile. Reagent and resin cost scale with chain length and the number of coupling cycles.

3.2 The Fermentation / Recombinant Route

In this route, the cell builds the chain, then an enzyme releases it.

• Advantage at scale. Fermentation forms the long chain in one biological event, so the input is a cell mass rather than many protected amino acids.

• Cost advantage. The variable cost base is lower at commercial scale, which is why the backbone is often made this way.

• The trade-off. The process needs a well-designed fusion and a reliable cleavage step, and the impurity profile is host- and fusion-related rather than chemical.

• The quality link. The expression strain, the enzyme, and the chromatography together decide the quality of the intermediate, so a route that controls all three is the one that delivers a stable batch history.

3.3 What the Route Does to the Impurity Profile

The route determines the kind of impurities, which drives the purification strategy.

• Fermentation impurities. Host proteins, fusion-related species, and truncated forms dominate. These are removed by the chromatographic step.

• Chemical impurities. Deletion sequences and epimers dominate. These require a different set of separation conditions.

• Practical effect. Knowing the route tells you what to test for and how much purification margin you need.

3.4 Matching the Route to Your Stage

The best route depends on where you are in development.

• Research scale. Chemical synthesis is often simpler to start, because you can build a small batch on demand without a fermentation pipeline.

• Pilot or process-development scale. The fermentation route starts to pay off as batch size grows and the upstream process is validated.

• Commercial scale. Fermentation is usually the more economical choice, since the variable cost base falls as scale rises and the long chain is made in one biological event.


4. Quality Attributes and How to Assess Them

The core conclusion first: assess a Semaglutide P29 peptide intermediate on four attributes, in order: purity, impurity control, batch consistency, and GMP documentation.

4.1 High Purity

Purity is the headline number, but it needs a defined basis.

• Area purity. The HPLC main-peak area percentage is a relative measure and the usual headline.

• Effective content. Check how much of the powder is actually the peptide, after water, counterion, and salt are accounted for.

• Specific activity / no residuals. For an intermediate, this maps to a clean identity and the absence of residual enzyme or host protein in the final material.

4.2 Controlled Impurities

A purity number alone is not enough.

• Ask for the impurity profile. A supplier that names the related substances and their source is more useful than one that only reports a main-peak percentage.

• Check the stage at which they appear. Some species exist before cleavage; others appear after, and some arise during storage.

• Verify the limit set. Confirm that the specification covers the impurities you actually have to control downstream.

4.3 Batch-to-Batch Consistency

Consistency is what a manufacturing process depends on.

• Look at trend data, not a single certificate. Ask for multiple batch records and the related-substance trend.

• Confirm the content basis is stable. Area purity can be stable while effective content drifts.

• Check the salt form and counterion. A change here changes the content basis and reconstitution behavior.

4.4 GMP Grade and Documentation

For commercial use, documentation is part of the product.

• GMP-grade material. Confirm whether the product is provided under Good Manufacturing Practice controls and what quality system governs it.

• The supporting file. Ask for the certificate of analysis with the actual assay basis, and any regulatory or stability data you need.

• Custom or regulated specification. Confirm whether the specification can be tailored to your process and application.

4.5 A Practical Assessment Workflow

Turn the attributes into a short, repeatable check.

• Step 1: confirm identity. Check the sequence, the N/C termini, the salt form, and the content basis.

• Step 2: review purity and impurities. Read the area purity together with the related-substance profile, not in isolation.

• Step 3: check consistency. Look at trend data across batches and confirm the content basis is stable.

• Step 4: confirm documentation. Verify the GMP grade, the certificate of analysis, and the ability to tailor the specification and packaging.

• Step 5: plan the enzyme fit. Confirm the complementary enzymes are available and matched to the precursor boundary you designed.

4.6 How Quality Maps to Downstream Cost

Better quality in the intermediate reduces cost downstream.

• Fewer purification steps. A cleaner feed into the modification step needs less separation, which raises recovery.

• Less rework. Consistent batches reduce the chance of an out-of-spec modification run that has to be reprocessed.

• Faster qualification. A material with a documented impurity profile and GMP status is quicker to release and to carry into a regulatory submission.


5. Complementary Enzymes and the Full Workflow

The core conclusion first: the intermediate is only half of the route. The enzymes that release and trim it determine how clean the final N-terminus and C-terminus are, and they are best matched to the precursor you designed.

 

Decision flow for matching the tool enzyme to the precursor boundary.

figure3. Decision flow for matching the tool enzyme to the precursor boundary.

5.1 Recombinant Enterokinase

Recombinant enterokinase releases a fusion tag at a specific sequence.

• Recognition site. It recognizes the Asp-Asp-Asp-Asp-Lys (DDDDK) sequence and cuts after the lysine, leaving a native N-terminus.

• The advantage. Because it cuts after the lysine, the released chain carries no extra residue from the recognition sequence.

• The attribute to look for. High specificity and high activity, so the cut is clean and the reaction is fast.

5.2 Recombinant Kex2 Protease

Kex2 is a yeast endoprotease that processes dibasic sites.

• Recognition site. It recognizes paired basic residues such as Arg-Arg and Lys-Arg, and cuts at the C-terminal side of the pair.

• The advantage. It is well suited to releasing a chain from a fusion precursor built around a dibasic junction.

• The attribute to look for. High activity and a clearest possible cut, to minimize mis-cleaved fragments.

5.3 Recombinant Carboxypeptidase B

Carboxypeptidase B trims C-terminal basic residues.

• The role. After release, if a C-terminal lysine or arginine remains, carboxypeptidase B removes it to give a defined terminus.

• The advantage. It handles the finishing step, converting the released peptide into the exact end-group you need.

• The caution. Free arginine, lysine, and EDTA in the buffer can affect its activity, so the buffer is designed before the enzyme dose is optimized.

5.4 Matching the Enzyme to the Precursor Boundary

Selection starts from the end you want, not from a catalog.

• Define the allowed-extra-residue budget. Decide what the N-terminus and C-terminus may carry.

• Design the linker around it. If you need a native N-terminus, a DDDDK linker with enterokinase is a clean choice. If you can tolerate a dibasic junction, Kex2 works. If you need C-terminal trimming, add carboxypeptidase B.

• Keep the tools together. When the intermediate and the processing enzymes come from one source, the route stays coherent and the enzyme choice stays aligned to the precursor you designed.

5.5 The MATWINGS MALL Semaglutide P29 peptide intermediate

The intermediate and its companion enzymes are offered as one coherent route, and the value is in the quality and the flexibility around it.

• High quality. The intermediate is produced with high purity and high specific activity, and the processing enzymes are designed to leave no residual tag or unwanted residue on the released chain. This is what a clean end-group depends on.

• GMP manufacturing. GMP-grade material can be provided, so the product is available for regulated manufacturing as well as for research and development.

• Diverse selection. Products can be chosen and combined according to the application scenario, which matters when your precursor boundary or modification chemistry is specific to your process.

• Customizable specifications. The specification and the form can be tailored to customer requirements, so the material matches your release tests rather than a fixed catalog sheet.

• Stable supply. Batch quality is stable and the supply is intended to be long-term, which reduces the risk of a mid-program supplier change.

• The companion enzymes. Recombinant enterokinase, recombinant Kex2 protease, and recombinant carboxypeptidase B are offered alongside the intermediate, so you can match the enzyme to the precursor boundary without a separate qualification.

This is a solution branch within the route, and it is sized to your actual need. If a standard product does not fit the boundary you designed, a custom intermediate or tool-enzyme development path is available around your specific sequence and end-point.

5.6 Choosing Between a Standard Product and a Custom Route

Most programs do not need a custom intermediate, and it helps to know the boundary.

• A standard product is enough when your precursor boundary is conventional, your modification chemistry is established, and the process scale is within the supplier's standard range.

• A custom route makes sense when your sequence or end-point is unusual, your impurity profile is the limiting factor, or you need a specification that a catalog sheet cannot meet.

• The right call is scoped. Custom development is a solution branch, not the default, and it should be sized to the specific process need rather than pursued for its own sake.


6. FAQ

6.1 What is the Semaglutide P29 peptide intermediate?

It is the 29-amino-acid backbone of semaglutide, also called the semaglutide 29-peptide backbone or Arg34GLP-1(9-37), CAS 1169630-82-3. It is the core chain to which the N-terminal extension and the fatty-acid side chain are attached to form the semaglutide API.

6.2 How is the Semaglutide P29 peptide intermediate produced?

It is usually produced by fermentation. A recombinant host is engineered to express a fusion precursor, the precursor is cut with a highly specific enzyme, the target peptide is isolated by medium-pressure preparative chromatography, and the product is lyophilized to a powder.

6.3 Is the intermediate the same as GLP-1(9-37)?

Yes in most commercial contexts, but the names are not a guarantee of identical material. Confirm the exact sequence, termini, salt form, and content basis for the specific sample, and check whether the material is a clean native N-terminus.

6.4 Which enzyme should I use to release the intermediate from its fusion precursor?

It depends on the junction you engineered. For a DDDDK linker, use recombinant enterokinase for a native N-terminus. For a dibasic site such as Arg-Arg or Lys-Arg, use Kex2. If a C-terminal basic residue remains, add carboxypeptidase B to trim it.

6.5 What should I check before buying the intermediate?

Verify the purity and the content basis, the impurity profile, the batch-to-batch consistency, the GMP grade and documentation, and whether the specification and packaging can be tailored to your process. For a route that depends on the precursor boundary, also confirm that the complementary enzymes are available from the same source.


Summary

The Semaglutide P29 peptide intermediate is the backbone that carries the identity of semaglutide, and its quality sets the ceiling for the API. It is most often made by fermentation, in a three-stage pipeline of recombinant expression, a highly specific enzyme cut, and medium-pressure preparative chromatography. The route you choose, chemical or fermentation, shapes the impurity profile, while the purity, impurity control, and batch consistency of the intermediate decide how cleanly the downstream modification can run. Because the processing enzyme is matched to the precursor boundary, the intermediate and the enzyme are best sourced together. A high-purity, GMP-grade intermediate with a stable batch history and a supporting enzyme set reduces downstream rework and speeds qualification, which is where the real value of the material lies.


Lock in your P29 solution with MATWINGS MALL

MATWINGS MALL supports semaglutide API development and manufacturing with the Semaglutide P29 peptide intermediate (29-amino-acid backbone, Arg34GLP-1(9-37), CAS 1169630-82-3), produced by a recombinant fermentation route and characterized by high purity, controlled impurities, and batch-to-batch consistency. We also supply the companion recombinant enterokinase, Kex2 protease, and carboxypeptidase B, so the enzyme set can be matched to your precursor boundary — recombinant enterokinase for a DDDDK linker to obtain a native N-terminus, Kex2 for a dibasic site (Arg-Arg / Lys-Arg), and carboxypeptidase B to trim a residual C-terminal basic residue. Products are available in GMP grade, selectable by application scenario, and offered with customized specification and form, supported by stable batch quality and long-term supply.

Where a standard product does not fit your sequence or end-point, we scope a custom intermediate or tool-enzyme development around your specific sequence and terminus. To request a sample or discuss a specification, visit the MATWINGS MALL product page / expert center.

 

Scan to join community

Scan to join community